Skip to content
BIO Investor Forum panel breaks down when, what, and why of IPOs
Biotech firms weighing an initial public offering (IPO) must consider timing, interest in ...
Read More
BIF 2024: ‘The IRA really disrupted how we think’
The Inflation Reduction Act (IRA) has been top of mind for many in ...
Read More
As Medicare open enrollment nears, seniors will face difficult choices despite CMS’ rosy assessment
Prescription drug coverage in Medicare will see sweeping changes – for both health ...
Read More
BIO Investor Forum opens with encouraging news on financing
The tide has been rising in biotech investment in 2024—though it has not ...
Read More
BIF 2024: What’s happening with neurodegenerative disease targets and pipelines?
There is a great degree of renewed optimism for drug development in the ...
Read More
How to follow the 2024 BIO Investor Forum in San Francisco
Bio.News is heading back to San Francisco for the Biotechnology Innovation Organization (BIO) ...
Read More
EDITORS' CHOICE
BIO Investor Forum opens with encouraging news on financing
The tide has been rising in biotech investment in 2024—though it has not lifted all boats equally. While the volume of investment improved in the ...
Read More
LATEST NEWS
BIO Events
BIO Investor Forum panel breaks down when, what, and why of IPOs
Biotech firms weighing an initial public offering (IPO) must consider timing, interest in their product, the macro environment—and whether they really need all the headaches, ...
BIO Events
BIF 2024: ‘The IRA really disrupted how we think’
The Inflation Reduction Act (IRA) has been top of mind for many in the biotech industry. The first round of price negotiations and the impending ...
BIO's View
As Medicare open enrollment nears, seniors will face difficult choices despite CMS’ rosy assessment
Prescription drug coverage in Medicare will see sweeping changes – for both health plans and for the millions of American seniors they serve – despite ...
BIO Events
BIO Investor Forum opens with encouraging news on financing
The tide has been rising in biotech investment in 2024—though it has not lifted all boats equally. While the volume of investment improved in the ...
BIO Events
BIF 2024: What’s happening with neurodegenerative disease targets and pipelines?
There is a great degree of renewed optimism for drug development in the neurodegenerative disease space. “Some of that optimism has obviously come from the ...
HEALTH
Welcome, John F. Crowley!
Get to know John F. Crowley, the new President and CEO of the Biotechnology Innovation Organization (BIO), in our exclusive interview.
AGRICULTURE
Climate Change
What to know about BIO’s 7 Core Strategic Priorities
With the 118th Congress wrapping up in a few months, the Biotechnology Innovation Organization (BIO) continues its work to improve ...
Read More
Federal Policy
State Policy
Virginia Gov. Youngkin named BIO’s Governor of the Year
Virginia Gov. Glenn Youngkin on Sept. 17 received the 2024 Governor of the Year Award from the Biotechnology Innovation Organization ...
Read More
International
Bio's View
As Medicare open enrollment nears, seniors will face difficult choices despite CMS’ rosy assessment
Prescription drug coverage in Medicare will see sweeping changes – for both health plans and for the millions of American ...
Read More
